References for Cell Lines in the Open Distribution List

QuickLinks:   Home » Protocols » Request Cell-lines » Download MTA » Contact
Characterization of Cell Lines
  1. Reynolds CP, Biedler JL, Spengler BA, Reynolds DA, Ross RA, Frenkel EP, Smith RG: Characterization of human neuroblastoma cell lines established before and after therapy. J National Cancer Institute 76:375-387, 1986.
  2. Keshelava N, Zuo JJ, Chen P, Waidyaratine SN, Luna MC, Gomer CJ, Triche TJ, Reynolds C P: Loss of p53 function confers high-level multi-drug resistance in neuroblastoma cell lines. Cancer Research 61:6185-6193, 2001.
  3. Reynolds CP, Brodeur GM, Tomayko MM, Donner L, Helson L, Seeger RC, Triche TJ: Biological classification of cell lines derived from human extra-cranial neural tumors. Prog Clin Biol Res 271:291-306, 1988.
  4. Wada RK, Seeger RC, Brodeur GM, Rayner SA, Tomayko MM, Reynolds CP: N-myc expression in human neuroblastoma cell lines without N-myc gene amplification, Cancer 72:3346-3354, 1993.
  5. Keshelava N, Seeger RC, Groshen S, Reynolds CP: Drug resistance patterns of human neuroblastoma cell lines derived from patients at different phases of therapy. Cancer Research 58:5396-5405, 1998.
  6. Whiteford CC, Bilke S, Greer BT, Braunschweig TA, Cenacchi N, Wei JS, Smith M, Houghton P, Reynolds CP, Lock R, Gorlick R, Khanna C, Thiele CJ, COG Phase 1 Consortium, Hewitt SM, Khan J: Credentialing preclinical pediatric xenograft models using gene expression and tissue microarray analysis. Cancer Research 67:32-40, 2007.
Research Using Neuroblastoma Cell Lines
  1. Anderson CP, Seeger RC, Satake N, Meek WE, Keshelava N, Bailey HH, Monforte-Munoz HL, Reynolds CP: Buthionine sulfoximine and myeloablative concentrations of melphalan overcome resistance in a melphalan-resistant neuroblastoma cell line. J Pediat Hematol Oncol 23:500-505, 2001.
  2. Roberts SS, Mori M, Pattee P, Lapidus J, Mathews R, O’Malley JP, Hsieh YC, Turner MA, Wang Z, Tian Q, Rodland MJ, Reynolds, CP, Seeger RC, Niagalla R: GABAnergic system gene expression predicts clinical outcome in patients with neuroblastoma. J Clinical Oncology 22:4127-4134, 2004.
  3. Yang B, Reynolds CP: Tirapazamine cytotoxicity for neuroblastoma is p53-dependent. Clinical Cancer Research 11:2774-2780, 2005.
  4. Houghton PJ, Morton CL, Tucker C, Payne D, Favours E, Cole C, Gorlick R, Kolb EA, Zhang W, Lock R, Carol H, Tajbakhsh M, Reynolds CP, Maris JM, Courtright J, Keir ST, Friedman HS, Stopford C, Zeidner J, Wu J, Liu T, Billups CA, Khan J, Ansher S, Zhang J, Smith MA: The Pediatric Preclinical Testing Program: Description of models and early testing results. Pediatric Blood & Cancer 49:928-940, 2007.
  5. Frgala T, Kalous O, Proffitt RT, Reynolds CP: A novel cytotoxicity assay with a 4 log dynamic range that identifies synergistic drug combinations. Molecluar Cancer Therapeutics 6:886-89, 2007.
  6. Keshelava N, Davicioni E, Zesheng Wan Z, Ji L, Sposto R, Triche TJ, Reynolds CP: Inhibition of histone deacetylase (HDAC) 1, a drug target identified by expression profiling, sensitizes multi-drug-resistant neuroblastoma cell lines to cytotoxic agents. J National Cancer Institute 99:1107-19, 2007.
  7. Maurer BJ, Kalous O, Yesair DW, Wu X, Vratilova J, Maldonado V, Khankaldyyan V, Frgala T, Sun BC, McKee RT, Burgess SW, Shaw WA, Reynolds CP: Improved oral delivery of N-(4-hydroxyphenyl)retinamide with novel LYM-X-SORBTM organized lipid complex in mice. Clinical Cancer Research 13:3079-3086, 2007.
  8. Peng H, Sohara Y, Moats RA, Nelson MD Jr, Groshen SG, Ye W, Reynolds CP, DeClerck YA: The activity of zoledronic acid on neuroblastoma bone metastasis involves inhibition of osteoclasts and ras-mediated tumor cell survival and proliferation. Cancer Research 67:9346-55, 2007.
  9. Grigoryan RS, Yang B, Keshelava N, Barnhart JR, Reynolds CP: Flow cytometry analysis of single strand DNA damage in neuroblastoma cell lines using the F7-26 monoclonal antibody. Cytometry Part A 71A:951-960, 2007.
  10. Harned TM, Kalous O, Neuwelt A, Loera J, Ji L, Iovine P, Sposto R, Neuwelt EA, Reynolds CP: Sodium Thiosulfate (STS) administered six hours after cisplatin does not compromise anti-neuroblastoma activity. Clinical Cancer Research 14:533-540, 2008.
Research Using EFT Cell Lines
  1. Batra S, Reynolds CP, Maurer BJ: Fenretinide cytotoxicity for Ewing's sarcoma (ES) and primitive neuroectodermal Tumor (PNET) cell lines is decreased by hypoxia and synergistically enhanced by ceramide modulators. Cancer Research 64:5415-5424, 2004.
Research Using Leukemia Cell Lines
  1. Kang MH, Kang YH, Szymanska B, Wilczynska-Kalak U, Sheard MA, Harned T, Lock RB, Reynolds CP: Activity of vincristine, L-ASP, and dexamethasone against acute lymphoblastic leukemia is enhanced by the BH3-mimetic ABT-737 in vitro and in vivo. Blood 110:205-2066, 2007.
  2. Kang MH, Wan Z, Kang YH, Locke RS, Reynolds CP: Enhanced activity of BH3-mimetic ABT-737 by fenretinide through Mcl-1-inactivation in acute lymphoblastic leukemia cells. J National Cancer Institute 100:580-595, 2008.
NCI Pediatric Preclinical Testing Program
  1. Maris JM, Courtright J, Houghton PJ, Morton CL, Gorlick R, Kolb EA, Lock R, Tajbakhsh M, Reynolds CP, Keir ST, Wu J, Smith MA: Initial testing (Stage 1) of the VEGFR inhibitor AZD2171 by the Pediatric Preclinical Testing Program. Pediatric Blood & Cancer 50:581-587, 2008
  2. Houghton PJ, Morton CL, Tucker C, Gorlick R, Kolb EA, Zhang W, Lock R, Carol H, Reynolds CP, Keshelava N, Maris JM, Courtright J, Keir ST, Friedman HS, Stopford C, Wu J, Smith MA: Stage 1 testing of the proteasome inhibitor bortezomib by the Pediatric Preclinical Testing Program. Pediatric Blood & Cancer 50:37-45, 2008.
  3. Kolb EA, Gorlick R, Houghton PJ, Morton CL, Lock R, Tajbakhsh M, Reynolds CP, Maris JM, Keir ST, Billups CA, Smith MA: Initial testing of dasatinib by the Pediatric Preclinical Testing Program. Pediatric Blood & Cancer 50:1198-1206, 2008.
  4. Tajbakhsh M, Houghton PJ, Morton CL, Kolb EA, Maris JM, Keir ST, Wu J, Reynolds CP, Smith MA, Lock RB: Initial testing (Stage 1) of cisplatin by the Pediatric Preclinical Testing Program. Pediatric Blood & Cancer (In Press, 2008).
  5. Houghton PJ, Morton CL, Kolb EA, Lock R, Reynolds CP, Maris JM, Keir ST, Billups CA, Tucker C, Smith MA: Initial testing (Stage 1) of the mTOR inhibitor rapamycin by the Pediatric Preclinical Testing Program. Pediatric Blood & Cancer 50:709-805, 2008.
  6. Lock R, Carol H, Houghton PJ, Morton CL, Kolb EA, Reynolds CP, Maris JM, Keir ST, Wu J, Smith MA: Initial testing (Stage 1) of the BH3 Mimetic ABT-263 by the Pediatric Preclinical Testing Program. Pediatric Blood & Cancer 50:1181-1189, 2008.
  7. Kolb EA, Gorlick R, Houghton PJ, Morton CL, Lock R, Carol H, Reynolds CP,
  8. Maris JM, Keir ST, Billups CA, Smith MA: Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program. Pediatr Blood Cancer 50:1190-1197, 2008.
  9. Smith MA, Morton CL, Phelps DA, Kolb EA, Lock R, Carol H, Reynolds CP, Maris
  10. JM, Keir ST, Wu J, Houghton PJ. Stage 1 testing and pharmacodynamic evaluation of the HSP90 inhibitor alvespimycin (17-DMAG, KOS-1022) by the pediatric preclinical testing program. Pediatric Blood & Cancer 51(1):34-41, 2008.
  11. Maris JM, Courtright J, Houghton PJ, Morton CL, Kolb EA, Lock R, Tajbakhsh M, Reynolds CP, Keir ST, Wu J, Smith MA. Initial testing (stage 1) of sunitinib by the pediatric preclinical testing program. Pediatric Blood & Cancer 51:42-8, 2008.
  12. Neal G, Su X, Morton CL, Phelps D, Gorlick R, Lock RB, Reynolds CP, Maris JM, Friedman HS, Dome J, Khoury J, Triche TJ, Seeger RC, Gilbertson R, Khan J, Smith MA, Houghton PJ: Molecular characterization of the Pediatric Preclinical Testing panel. Clinical Cancer Research 14:4572-83, 2008.
 

© Texas Tech University Health Sciences Center (2008-2010)
Shown are confocal images of CHLA-90 (above), and FU-NB-2006 (left).
Confocal images by Felicia Codrea.